AgeneBio Founder Michela Gallagher Presents Hope4MCI Results at 12th Alzheimer’s & Parkinson’s Drug Development Summit

Examining Progression in MCI Due to AD: Results from a Phase 2b Trial of AGB101 Using high resolution structural brain imaging to monitor brain atrophy as a biomarker of progression Consistent with a decrease in clinical and cognitive progression (CDR sum of boxes), brain atrophy was reduced by AGB101 compared to placebo in a 78-week…